Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Brain Cancer, Blood Cancer, Blood Cancer, Lymphoma, Hematology, Hematology, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 4/21/2016 |
| Start Date: | August 2008 |
| End Date: | October 2009 |
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help
doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who
were treated on a clinical trial to control nausea and vomiting during donor stem cell
transplant.
doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who
were treated on a clinical trial to control nausea and vomiting during donor stem cell
transplant.
OBJECTIVES:
Primary
- To compare the amount of substance P in serum samples from patients with cancer treated
with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning
regimens prior to undergoing allogeneic hematopoietic stem cell transplantation.
Secondary
- To assess the changes in substance P over time to see if there is an optimal time shown
by this physiologic correlate to discontinue substance P blockade after the
chemotherapy regimen is completed in these patients.
OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes
in substance P levels.
Patients' medical records are reviewed for demographic information, past history, and course
of treatment.
Primary
- To compare the amount of substance P in serum samples from patients with cancer treated
with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning
regimens prior to undergoing allogeneic hematopoietic stem cell transplantation.
Secondary
- To assess the changes in substance P over time to see if there is an optimal time shown
by this physiologic correlate to discontinue substance P blockade after the
chemotherapy regimen is completed in these patients.
OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes
in substance P levels.
Patients' medical records are reviewed for demographic information, past history, and course
of treatment.
DISEASE CHARACTERISTICS:
- Previously collected serum samples from patients with cancer enrolled on the placebo
arm of the pilot aprepitant study
- Patients treated with busulfan/cyclophosphamide or cyclophosphamide/total body
irradiation conditioning regimens prior to undergoing allogeneic hematopoietic
stem cell transplantation
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
We found this trial at
1
site
OHSU Knight Cancer Institute OHSU Knight Cancer Institute is known worldwide for our contributions to...
Click here to add this to my saved trials
